LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Home・Stock List・Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals Inc

Closed

SectorHealthcare

24.93 -0.87

Buy Sell

Overview

Share price change

24h

Current

Min

24.82

Max

24.98

Key metrics
By Trading Economics
Income	258M 216M
Sales	280M 459M
P/E Sector Avg	68.649 78.892
EPS	1.67
Profit margin	47.04
Employees	705
EBITDA	258M 228M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+69.12% upside

Market Stats
By TradingEconomics
Market Cap	-547M 3.2B
Previous open	25.8
Previous close	24.93

News Sentiment

By Acuity

50%

149 / 374 Healthcare

Apellis Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Dec 2025, 21:41 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

28 Dec 2025, 23:57 UTC

Earnings

'Avatar: Fire and Ash' Tops Domestic Box Office Again -- Barrons.com

28 Dec 2025, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 Dec 2025, 23:48 UTC

Market Talk

Global Equities Roundup: Market Talk

28 Dec 2025, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

28 Dec 2025, 10:30 UTC

Acquisitions, Mergers, Takeovers

There's No Happy Ending for Movie Theaters, No Matter Who Wins Warner -- Heard on the Street -- WSJ

26 Dec 2025, 20:22 UTC

Market Talk

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 Dec 2025, 20:13 UTC

Market Talk

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 Dec 2025, 19:24 UTC

Acquisitions, Mergers, Takeovers

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 Dec 2025, 17:45 UTC

Market Talk

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 Dec 2025, 15:52 UTC

Market Talk

Oil Futures Turn Lower After Steady Start -- Market Talk

26 Dec 2025, 14:58 UTC

Market Talk

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 Dec 2025, 14:41 UTC

Market Talk

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 Dec 2025, 14:28 UTC

Market Talk

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 Dec 2025, 13:47 UTC

Market Talk

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 Dec 2025, 07:22 UTC

Market Talk

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 Dec 2025, 05:03 UTC

Market Talk

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 Dec 2025, 03:38 UTC

Market Talk

Global Equities Roundup: Market Talk

26 Dec 2025, 03:38 UTC

Market Talk

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 Dec 2025, 02:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

26 Dec 2025, 02:44 UTC

Market Talk

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 Dec 2025, 01:39 UTC

Market Talk

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 Dec 2025, 01:14 UTC

Market Talk

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 Dec 2025, 00:34 UTC

Market Talk

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 Dec 2025, 00:15 UTC

Market Talk

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 Dec 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 Dec 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 Dec 2025, 00:20 UTC

Acquisitions, Mergers, Takeovers

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 Dec 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 Dec 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

Peer Comparison

Price change

Apellis Pharmaceuticals Inc Forecast

Price Target

By TipRanks

69.12% upside

12 Months Forecast

Average 42.23 USD 69.12%

High 117.8 USD

Low 22 USD

Based on 15 Wall Street analysts offering 12 month price targets forApellis Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

Buy

Hold

Sell

Based on 15 analysts giving stock ratings to Apellis Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

149 / 374 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.